Akuter und chronischer Husten – Differenzialdiagnose und Behandlung

Husten ist ein häufiger Konsultationsgrund in der hausärztlichen Praxis. Meist ist das Symptom harmlos und selbstlimitierend wie z. B. bei einem banalen Erkältungshusten – jedoch können auch schwerwiegende Erkrankungen wie Malignome die Ursache sein. Die Abklärung ist daher nicht immer einfach. Dieser Beitrag stellt ein gezieltes und angemessenes Vorgehen dar und diskutiert, welche Behandlungen empfohlen und effektiv sind.

Abstract

Cough is a frequent reason for consultation in the general practitionerʼs office. Most of the time, the symptom is harmless and self-limiting, as in the case of a banal cold cough, for example – however, serious diseases such as malignancies can also be the cause. Evaluation is therefore not always easy. This article presents a targeted and appropriate approach and discusses which treatments are recommended and effective.

Acute and chronic cough are differentiated according to the duration of symptoms (up to 8 weeks/longer than 8 weeks). The most common cause of acute cough is a self-limiting viral infection of the upper respiratory tract; the most important differential diagnosis is community-acquired pneumonia. If there are no defined warning signs (red flags), the history and clinical examination are sufficient to establish the diagnosis in the case of an acute cough; medication is not necessary. In the case of a chronic cough, a chest X-ray is usually ordered and then further investigations are carried out in accordance with the most probable suspected diagnosis; probationary therapies are an important part of the workup. Coughs that are refractory to treatment or unexplained require individualised treatment (pharmacological, including off-label, non-pharmacological) and regular re-evaluation.

Schlüsselwörter

akuter Husten - chronischer Husten - Hausarztpraxis - Differenzialdiagnose

Key words

acute cough - chronic cough - family practice - differential diagnosis

Publikationsverlauf

Artikel online veröffentlicht:
01. August 2022

• Literatur

• 1 Laux G, Rosemann T, Körner T. et al. Detailed data collection regarding the utilization of medical services, morbidity, course of illness and outcomes by episode-based documentation in general practices within the CONTENT project. Gesundheitswesen 2007; 69: 284-291
• 2 Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet 2008; 371: 1364-1374
• 3 Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA). Volkswirtschaftliche Kosten durch Arbeitsunfähigkeit 2018. https://www.baua.de/DE/Themen/Arbeitswelt-und-Arbeitsschutz-im-Wandel/Arbeitsweltberichterstattung/Kosten-der-AU/Kosten-der-Arbeitsunfaehigkeit_node.html [2021-05-20]
• 4 Krüger K, Gehrke-Beck S, Holzinger F. et al. S3 Leitlinie akuter und chronischer Husten der Deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). AWMF Online 2021: AWMF-Register-Nr. 053-013.
• 5 Altiner A, Wilm S, Däubener W. et al. Sputum colour for diagnosis of a bacterial infection in patients with acute cough. Scand J Prim Health Care 2009; 27: 70-73
• 6 van der Meer V, Neven AK, van den Broek PJ. et al. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ (Clinical research ed) 2005; 331: 26
• 7 van Vugt SF, Broekhuizen BDL, Lammens C. et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ 2013; 346: f2450
• 8 Holm A, Pedersen SS, Nexoe J. et al. Procalcitonin versus Creactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract 2007; 57: 555-560
• 9 Huang Y, Chen R, Wu T. et al. Association between point-ofcare CRP testing and antibiotic prescribing in respiratory tract infections: a systematic review and meta-analysis of primary care studies. Br J Gen Pract 2013; 63: e787-e794
• 10 Schuetz P, Wirz Y, Sager R. et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochr Data Syst Rev 2017; 10: Cd007498
• 11 Wood F, Brookes-Howell L, Hood K. et al. A multi-country qualitative study of cliniciansʼ and patientsʼ views on point of care tests for lower respiratory tract infection. Fam Pract 2011; 28: 661-669
• 12 Smith SM, Fahey T, Smucny J. et al. Antibiotics for acute bronchitis. Cochr Data Syst Rev 2017;
• 13 Sierocinski E, Holzinger F. Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review. Eur J Clin Pharmacol 2021; 77: 1113-1122
• 14 Matthys H, de Mey C, Carls C. et al. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. Arzneimittelforschung 2000; 50: 700-711
• 15 Kemmerich B, Eberhardt R, Stammer H. Efficacy and tolerability of a fluid extract combination of thyme herb and ivy leaves and matched placebo in adults suffering from acute bronchitis with productive cough. A prospective, doubleblind, placebo-controlled clinical trial. Arzneimittelforschung 2006; 56: 652-660
• 16 Spurling GK, Del Mar CB, Dooley L. et al. Delayed antibiotic prescriptions for respiratory infections. Cochr Data Syst Rev 2017; 9: Cd004417
• 17 Coxeter P, Del Mar CB, McGregor L. et al. Interventions to facilitate shared decision making to address antibiotic use for acute respiratory infections in primary care. Cochr Data Syst Rev 2015; 2015: Cd010907
• 18 McNally M, Curtain J, OʼBrien KK. et al. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis. Br J Gen Pract 2010; 60: e423-e433
• 19 Ewig S, Kolditz M, Pletz M. et al. Leitlinie Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie – Update 2021. AWMF Online 2021: AWMF-Register-Nr. 020-020.
• 20 Irwin RS, French CL, Chang AB. et al. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest 2018; 153: 196-209
• 21 Smith JA, Kitt MM, Morice AH. et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Resp Med 2020; 8: 775-785